dc.contributor.author | Short, PJ | |
dc.contributor.author | McRae, JF | |
dc.contributor.author | Gallone, G | |
dc.contributor.author | Sifrim, A | |
dc.contributor.author | Won, H | |
dc.contributor.author | Geschwind, DH | |
dc.contributor.author | Wright, CF | |
dc.contributor.author | Firth, HV | |
dc.contributor.author | Fitzpatrick, DR | |
dc.contributor.author | Barrett, JC | |
dc.contributor.author | Hurles, ME | |
dc.date.accessioned | 2019-01-30T16:01:00Z | |
dc.date.issued | 2018-03-21 | |
dc.description.abstract | We previously estimated that 42% of patients with severe developmental disorders carry pathogenic de novo mutations in coding sequences. The role of de novo mutations in regulatory elements affecting genes associated with developmental disorders, or other genes, has been essentially unexplored. We identified de novo mutations in three classes of putative regulatory elements in almost 8,000 patients with developmental disorders. Here we show that de novo mutations in highly evolutionarily conserved fetal brain-active elements are significantly and specifically enriched in neurodevelopmental disorders. We identified a significant twofold enrichment of recurrently mutated elements. We estimate that, genome-wide, 1-3% of patients without a diagnostic coding variant carry pathogenic de novo mutations in fetal brain-active regulatory elements and that only 0.15% of all possible mutations within highly conserved fetal brain-active elements cause neurodevelopmental disorders with a dominant mechanism. Our findings represent a robust estimate of the contribution of de novo mutations in regulatory elements to this genetically heterogeneous set of disorders, and emphasize the importance of combining functional and evolutionary evidence to identify regulatory causes of genetic disorders. | en_GB |
dc.description.sponsorship | Health Innovation Challenge Fund | en_GB |
dc.description.sponsorship | Wellcome Trust | en_GB |
dc.description.sponsorship | UK Department of Health | en_GB |
dc.description.sponsorship | Wellcome Trust Sanger Institute | en_GB |
dc.identifier.citation | Vol. 555, pp. 611 - 616 | en_GB |
dc.identifier.doi | 10.1038/nature25983 | |
dc.identifier.grantnumber | HICF-1009-003 | en_GB |
dc.identifier.grantnumber | WT098051 | en_GB |
dc.identifier.uri | http://hdl.handle.net/10871/35670 | |
dc.language.iso | en | en_GB |
dc.publisher | Nature Research | en_GB |
dc.rights | © 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved. | en_GB |
dc.title | De novo mutations in regulatory elements in neurodevelopmental disorders | en_GB |
dc.type | Article | en_GB |
dc.date.available | 2019-01-30T16:01:00Z | |
dc.identifier.issn | 0028-0836 | |
dc.description | This is the author accepted manuscript. The final version is available from Nature Research via the DOI in this record | en_GB |
dc.identifier.journal | Nature | en_GB |
dc.rights.uri | http://www.rioxx.net/licenses/all-rights-reserved | en_GB |
dcterms.dateAccepted | 2018-01-24 | |
rioxxterms.version | AM | en_GB |
rioxxterms.licenseref.startdate | 2018-01-24 | |
rioxxterms.type | Journal Article/Review | en_GB |
refterms.dateFCD | 2019-01-30T15:57:53Z | |
refterms.versionFCD | AM | |
refterms.dateFOA | 2019-01-30T16:01:02Z | |
refterms.panel | A | en_GB |